SCHEMBL9944277

SCHEMBL9944277

CCOc1c(Br)cc(C(=O)Nc2ccc(C=O)c(C)c2)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.51
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
TP53 P04637 7/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 3/20 0.46
LMNA P02545 1/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
KDM4E B2RXH2 3/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.44
HPSE Q9Y251 1/20 0.43
HSP90AA1 P07900 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944349 0.90 MAPT (0.50) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944189 0.83 MAPT (0.54) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944336 0.83 TP53 (0.51) MAPTKMT2ATP53SMN1; SMN2ALDH1A1
SCHEMBL9944303 0.83 MEN1 (0.51) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL1458178 0.82 MAPT (0.56) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944331 0.81 RAB9A (0.49) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944302 0.81 MEN1 (0.49) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944208 0.79 MAPT (0.52) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944304 0.79 MAPT (0.50) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL9944150 0.78 MAPT (0.54) MAPTKMT2AMEN1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885KMT2A 1418/4885MEN1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.